Quantitative and Qualitative QC of Next-Generation Sequencing for Detecting Somatic Variants: An Example of Detecting Clonal Hematopoiesis of Indeterminate Potential.

BACKGROUND Because next-generation sequencing (NGS) for detecting somatic mutations has been adopted in clinical fields, both qualitative and quantitative QC of the somatic variants through whole coding regions detected by NGS is crucial. However, specific applications or guidelines, especially for quantitative QC, are currently insufficient. Our goal was to devise a practical approach for both quantitative and qualitative QC using an example of detecting clonal hematopoiesis of indeterminate potential (CHIP). METHODS We applied the QC scheme using commercial reference materials and in-house QC materials (IQCM) composed of haplotype map and cancer cell lines for monitoring CHIP. RESULTS This approach efficiently validated a customized CHIP NGS assay. Accuracy, analytical sensitivity, analytical specificity, qualitative precision (concordance), and limit of detection achieved were 99.87%, 98.53%, 100.00%, 100.00%, and 1.00%, respectively. The quantitative precision analysis also had a higher CV percentage at a lower alternative read depth (R2 = 0.749∼0.858). Use of IQCM ensured more than 100-fold reduction in the cost per run compared with that achieved using commercial reference materials. CONCLUSION Our approach determined the general analytical performance of NGS for detecting CHIP and recognized limitations such as lower precision at a lower level of variant burden. This approach could also be theoretically expanded to a general NGS assay for detecting somatic variants. Considering the reliable NGS results and cost-effectiveness, we propose the use of IQCM for QC of NGS assays at clinical laboratories.

[1]  C. Schlötterer,et al.  Sequencing pools of individuals — mining genome-wide polymorphism data without big funding , 2014, Nature Reviews Genetics.

[2]  Euan A. Ashley,et al.  Medical implications of technical accuracy in genome sequencing , 2016, Genome Medicine.

[3]  S. Miyano,et al.  Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. , 2015, The New England journal of medicine.

[4]  H. McLeod,et al.  Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. , 2017, The Lancet. Oncology.

[5]  Erika J. Thompson,et al.  Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study , 2016, The Lancet. Oncology.

[6]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[7]  Robin D Harrington,et al.  Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays. , 2016, The Journal of molecular diagnostics : JMD.

[8]  Ira W. Deveson,et al.  Reference standards for next-generation sequencing , 2017, Nature Reviews Genetics.

[9]  Ira W. Deveson,et al.  Spliced synthetic genes as internal controls in RNA sequencing experiments , 2016, Nature Methods.

[10]  Roberta Bordoni,et al.  Next Generation Sequencing of Pooled Samples: Guideline for Variants’ Filtering , 2016, Scientific Reports.

[11]  V. Jobanputra,et al.  Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer , 2018, The Journal of molecular diagnostics : JMD.

[12]  Christopher W. Wong,et al.  Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. , 2016, The Journal of molecular diagnostics : JMD.

[13]  Alexa B. R. McIntyre,et al.  Extensive sequencing of seven human genomes to characterize benchmark reference materials , 2015, Scientific Data.

[14]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[15]  D. Hayes,et al.  Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays , 2018, Clinical Cancer Research.

[16]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[17]  Chunlin Xiao,et al.  An open resource for accurately benchmarking small variant and reference calls , 2019, Nature Biotechnology.

[18]  S. Kathiresan,et al.  Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[19]  Jan P. Dumanski,et al.  Mosaicism in health and disease — clones picking up speed , 2016, Nature Reviews Genetics.

[20]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[21]  Naomi Porret,et al.  Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use , 2018, Blood Cancer Journal.

[22]  M. Ladanyi,et al.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. , 2017, Cell stem cell.

[23]  Marina N Nikiforova,et al.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[24]  Yuan Qi,et al.  Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.

[25]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[26]  E. Papaemmanuil,et al.  Managing Clonal Hematopoiesis in Patients With Solid Tumors. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.